Scandion Oncology Ownership
| SCOL Stock | SEK 0.06 0.01 9.70% |
Scandion |
Scandion Stock Ownership Analysis
The company has price-to-book ratio of 1.01. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Scandion Oncology recorded a loss per share of 1.74. The entity had not issued any dividends in recent years. Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. The company was founded in 2017 and is based in Copenhagen, Denmark. Scandion Oncology operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people. To find out more about Scandion Oncology AS contact Johnny MS at 45 38 10 20 17 or learn more at https://www.scandiononcology.com.Scandion Oncology Outstanding Bonds
Scandion Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Scandion Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Scandion bonds can be classified according to their maturity, which is the date when Scandion Oncology AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.